Brian Rubenstein ’21 pitched ThermoFisher Scientific (NYSE: TMO) on October 26th, 2020. ThermoFisher, the leading Life Sciences Tools & Services supplier globally, gives the portfolio risk-averse exposure to the drug development and manufacturing space. The company has a proven track record of retaining high market share through strategic business segmentation into Lab Products & Services, Life Sciences, Analytical Instruments and Specialty Diagnostics. With the broadest and most diversified product offerings, ThermoFisher has established themselves as a one-stop-shop for all thing’s laboratory supply. The company should continue to see dominance through viable growth strategies in their LPS and Analytical Instruments business segments coupled with the recent rapid rebound in the clinical trials pipeline and private investment capital to the industry. The class voted to buy 100 shares of TMO at an executed price of $475 and sell all remaining shares of the XHI and XBI healthcare ETFs.